New Data on Long-Acting Investigational Medication for HIV Prevention
We’ve announced topline results from an interim analysis of a clinical trial of our investigational medication for HIV prevention. This is the second Phase 3 trial to demonstrate the efficacy and safety profile for this medication. The first trial, PURPOSE 1 — which studied HIV prevention among cisgender women in sub-Saharan Africa — was unblinded early because it met key efficacy endpoints.
Our Purpose
We’ve been taking on the world’s biggest health challenges for more than 35 years. We continue to set and achieve ambitious goals to create a healthier world for all people.
Our MissionRecent Stories
Join Our Team
We're Hiring